atomoxetine + Matching Placebo
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease, Chorea
Trial Timeline
Nov 1, 2005 → Feb 1, 2008
NCT ID
NCT00368849About atomoxetine + Matching Placebo
atomoxetine + Matching Placebo is a phase 2 stage product being developed by Eli Lilly for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT00368849. Target conditions include Huntington Disease, Chorea.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00368849 | Phase 2 | Completed |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 77 |
| Votoplam | Novartis | Phase 2 | 52 |
| Branaplam + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |
| Tominersen + Placebo | Roche | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 3 | 77 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| RO7234292 + Placebo | Roche | Phase 3 | 77 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| Dextromethorphan + Dimebon + Dextromethorphan | Pfizer | Phase 1 | 32 |
| Dimebon | Pfizer | Phase 3 | 76 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 76 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Riluzole | Sanofi | Phase 3 | 76 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |
| Valbenazine | Neurocrine Biosciences | Phase 3 | 74 |